Precedex, Dexdor(dexmedetomidine)
Dexdor, Dexmedetomidine, Igalmi, Precedex (dexmedetomidine) is a small molecule pharmaceutical. Dexmedetomidine was first approved as Precedex on 1999-12-17. It is used to treat pain and psychomotor agitation in the USA. It has been approved in Europe to treat conscious sedation and premedication.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Dexmedetomidine, Igalmi, Precedex (discontinued: Dexmedetomidine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dexmedetomidine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| IGALMI | Bioxcel Therapeutics | N-215390 RX | 2022-04-05 | 2 products, RLD, RS |
| PRECEDEX | Hospira | N-021038 RX | 1999-12-17 | 5 products, RLD, RS |
| DEXMEDETOMIDINE HYDROCHLORIDE | HQ Specialty Pharma | N-206628 RX | 2015-10-21 | 4 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dexmedetomidine | ANDA | 2025-02-11 |
| dexmedetomidine dexmedetomidine hydrochloride | ANDA | 2023-06-01 |
| dexmedetomidine dexmedetomidine in dextrose | New Drug Application | 2025-03-11 |
| dexmedetomidine hcl | ANDA | 2023-05-04 |
| dexmedetomidine hydrochloride | ANDA | 2025-06-26 |
| dexmedetomidine hydrochloride dexmedetomidine hydrochloride in dextrose | New Drug Application | 2021-12-31 |
| dexmedetomidine hydrochloride in 0.9% sodium chloride | ANDA | 2024-11-06 |
| dexmedetomidine hydrochloride in sodium chloride | ANDA | 2023-12-21 |
| igalmi | New Drug Application | 2022-12-14 |
| precedex | New Drug Application | 2025-06-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pain | EFO_0003843 | D010146 | R52 |
| psychomotor agitation | — | D011595 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DEXMEDETOMIDINE HYDROCHLORIDE, PRECEDEX, HOSPIRA | |||
| 2025-12-16 | NPP | ||
DEXMEDETOMIDINE HYDROCHLORIDE, IGALMI, BIOXCEL | |||
| 2025-04-05 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Dexmedetomidine Hydrochloride, Igalmi, Bioxcel | |||
| 10792246 | 2039-06-26 | DP | U-3350 |
| 11478422 | 2039-06-26 | DP | |
| 11497711 | 2039-06-26 | DP | U-3645 |
| 11517524 | 2039-06-26 | DP | U-3645 |
| Dexmedetomidine Hydrochloride, Dexmedetomidine Hydrochloride, Hq Spclt Pharma | |||
| 9649296 | 2036-04-20 | DP | |
| 9717796 | 2036-04-20 | DP | |
| Dexmedetomidine Hydrochloride, Precedex, Hospira | |||
| 8242158 | 2032-01-04 | DP | |
| 8338470 | 2032-01-04 | DP | |
| 8455527 | 2032-01-04 | U-421 | |
| 8648106 | 2032-01-04 | DP | |
| 9320712 | 2032-01-04 | DP | |
| 9616049 | 2032-01-04 | DP | |
| 10016396 | 2032-01-04 | DP | |
HCPCS
No data
Clinical
Clinical Trials
1897 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | 9 | 29 | 24 | 47 | 89 | 182 |
| Delirium | D003693 | — | R41.0 | 10 | 13 | 17 | 53 | 50 | 138 |
| Anesthesia | D000758 | — | — | 7 | 9 | 20 | 31 | 52 | 115 |
| Emergence delirium | D000071257 | — | — | 13 | 8 | 14 | 32 | 41 | 101 |
| Analgesia | D000698 | — | — | 2 | 4 | 9 | 18 | 30 | 60 |
| Pain | D010146 | EFO_0003843 | R52 | 5 | 6 | 6 | 18 | 20 | 54 |
| Psychomotor agitation | D011595 | — | — | 6 | 13 | 13 | 15 | 12 | 53 |
| Agnosia | D000377 | EFO_0007136 | F88 | 2 | 5 | 9 | 15 | 16 | 44 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 2 | 3 | 3 | 7 | 16 | 29 |
| Cognitive dysfunction | D060825 | — | G31.84 | 2 | 1 | 1 | 14 | 12 | 29 |
Show 345 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hernia | D006547 | — | K40-K46 | 1 | 1 | 2 | — | 6 | 9 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 2 | 2 | 1 | — | 2 | 7 |
| Laparoscopy | D010535 | — | — | — | 1 | 2 | — | 4 | 6 |
| Cholecystectomy | D002763 | — | — | — | — | 2 | — | 4 | 6 |
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | — | 4 | 5 |
| Traumatic stress disorders | D040921 | — | — | 1 | 1 | 1 | — | 2 | 5 |
| Post-dural puncture headache | D051299 | — | — | 1 | — | 1 | — | 3 | 5 |
| Dementia | D003704 | EFO_0003862 | F03 | 1 | 3 | 2 | — | — | 5 |
| Cardiopulmonary bypass | D002315 | — | — | — | 2 | 2 | — | 3 | 5 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 1 | 2 | 1 | — | 2 | 5 |
Show 70 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | 1 | 2 | — | — | 1 | 4 |
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 1 | 2 | — | — | 1 | 4 |
| Tachycardia | D013610 | — | R00.0 | — | 1 | — | — | 3 | 4 |
| Autism spectrum disorder | D000067877 | — | F84.0 | — | 2 | — | — | 2 | 4 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | 2 | 3 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | 1 | — | — | 2 | 3 |
| Burns | D002056 | — | T30.0 | 1 | 2 | — | — | 1 | 3 |
| Hematoma | D006406 | EFO_0010680 | — | 1 | 1 | — | — | 2 | 3 |
| Critical care | D003422 | — | — | — | 1 | — | — | 2 | 3 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | — | — | 1 | 2 |
Show 35 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumoperitoneum | D011027 | — | — | 1 | — | — | — | 2 | 3 |
| Amnesia | D000647 | EFO_1001454 | F44.0 | 2 | — | — | — | 1 | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 2 | — | — | — | — | 2 |
| Gastric emptying | D005746 | — | — | 1 | — | — | — | 1 | 2 |
| Hypoplastic left heart syndrome | D018636 | — | Q23.4 | 2 | — | — | — | — | 2 |
| Memory disorders | D008569 | — | — | 1 | — | — | — | 1 | 2 |
| Percutaneous nephrolithotomy | D000074642 | — | — | 1 | — | — | — | 1 | 2 |
| Emotions | D004644 | — | — | 1 | — | — | — | — | 1 |
| Vital signs | D055986 | EFO_0004303 | — | 1 | — | — | — | — | 1 |
| Vasodilation | D014664 | — | — | 1 | — | — | — | — | 1 |
Show 21 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | — | — | — | — | 5 | 5 |
| Morphine dependence | D009021 | EFO_0005612 | — | — | — | — | — | 4 | 4 |
| Nociceptive pain | D059226 | — | — | — | — | — | — | 4 | 4 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 4 | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 2 | 2 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 2 | 2 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 2 | 2 |
| Hypokalemia | D007008 | — | E87.6 | — | — | — | — | 2 | 2 |
| Hemostatic disorders | D020141 | — | — | — | — | — | — | 2 | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | — | — | — | 2 | 2 |
Show 172 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dexmedetomidine |
| INN | dexmedetomidine |
| Description | Dexmedetomidine is a medetomidine. It has a role as an alpha-adrenergic agonist, a non-narcotic analgesic, an analgesic and a sedative. It is an enantiomer of a levomedetomidine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cccc([C@H](C)c2c[nH]cn2)c1C |
Identifiers
| PDB | — |
| CAS-ID | 113775-47-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL778 |
| ChEBI ID | 4466 |
| PubChem CID | 5311068 |
| DrugBank | DB00633 |
| UNII ID | 67VB76HONO (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Precedex – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 27,405 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,774 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use